4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Enhanced dopamine-dependent hippocampal plasticity after single MK-801 application.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dopaminergic hyperfunction and N-methyl-D-aspartate receptor (NMDAR) hypofunction have both been implicated in psychosis. Dopamine-releasing drugs and NMDAR antagonists replicate symptoms associated with psychosis in healthy humans and exacerbate symptoms in patients with schizophrenia. Though hippocampal dysfunction contributes to psychosis, the impact of NMDAR hypofunction on hippocampal plasticity remains poorly understood. Here, we used an NMDAR antagonist rodent model of psychosis to investigate hippocampal long-term potentiation (LTP). We found that single systemic NMDAR antagonism results in a region-specific, presynaptic LTP at hippocampal CA1-subiculum synapses that is induced by activation of D1/D5 dopamine receptors and modulated by L-type voltage-gated Ca(2+) channels. Thereby, our findings may provide a cellular mechanism how NMDAR antagonism can lead to an enhanced hippocampal output causing activation of the hippocampus-ventral tegmental area-loop and overdrive of the dopamine system.

          Related collections

          Author and article information

          Journal
          Neuropsychopharmacology
          Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
          Springer Nature
          1740-634X
          0893-133X
          Mar 2015
          : 40
          : 4
          Affiliations
          [1 ] 1] Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Berlin, Germany [2] Institute of Neurophysiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
          [2 ] Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité - Universitätsmedizin Berlin, Berlin, Germany.
          [3 ] Institute of Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
          [4 ] Institute of Neurophysiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
          [5 ] 1] Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité - Universitätsmedizin Berlin, Berlin, Germany [2] Cluster of Excellence NeuroCure, Charité - Universitätsmedizin Berlin, Berlin, Germany.
          [6 ] Neuroscience Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
          [7 ] 1] Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Berlin, Germany [2] Institute of Neurophysiology, Charité - Universitätsmedizin Berlin, Berlin, Germany [3] Department of Psychiatry and Psychotherapy, Ruppiner Kliniken, Neuruppin, Germany.
          Article
          npp2014276
          10.1038/npp.2014.276
          4330513
          25315194
          ea193b40-b66b-47c4-afa9-782161da14d9
          History

          Comments

          Comment on this article